NOVATO, Calif., Nov. 14, 2018 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that it has completed a pre-NDA meeting with the U.S. Food and Drug Administration (FDA) and plans to submit a New Drug Application […]Continue Reading ...
THURSDAY, Nov. 15, 2018 — For patients with breast cancer, reconstruction with autologous fat transfer (AFT) seems not to increase the rate of locoregional recurrence versus conventional breast reconstruction, according to a study published online Oct. 10 in JAMA Surgery. Todor Krastev, M.D., Ph.D., from the Maastricht University Medical Center in the Netherlands, and colleagues […]Continue Reading ...
Patients who have persistently high levels of inflammation following percutaneous coronary intervention (PCI) for coronary artery disease are significantly more likely to die from any cause or to have a heart attack within a year, according to a study of 7,026 patients published in the European Heart Journal. Residual inflammatory risk (RIR) refers to the […]Continue Reading ...
SAN DIEGO, Nov. 9, 2018 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, announced data from the ongoing Phase 2 clinical trial of mocetinostat in combination with durvalumab (IMFINZI®) in non-small cell lung cancer (NSCLC) patients at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting in Washington, D.C. The […]Continue Reading ...
A woman wears this soft and flexible groundbreaking new sensor, developed by the Rogers Research Group at Northwestern University, which uses measurements of temperature and heat transfer to non-invasively tell if and how much fluid is flowing through a shunt in a hydrocephalus patient. In the study, the skin sensor allowed hydrocephalus patients to see […]Continue Reading ...
Before patients receive intravenous (IV) antimicrobial infusion therapy outside of the hospital—whether at home, a doctor’s office or a skilled nursing facility—an infectious diseases (ID) specialist should review the order to ensure the most appropriate treatment, suggest updated guidelines released by the Infectious Diseases Society of America (IDSA). Once they begin receiving outpatient parenteral antimicrobial […]Continue Reading ...
A triple therapy combining two immune checkpoint inhibitors (ICPIs) with the standard-of-care chemotherapy, a hypomethylating agent called azacitidine, has shown promising results for treatment of relapsed or refractory acute myeloid leukemia (AML), according to findings from a Phase II study at The University of Texas MD Anderson Cancer Center. Findings from the study, led by […]Continue Reading ...
How can a doctor predict the treatment outcome of an individual patient? Traditionally, the effectiveness of medical treatments is studied by randomized trials where patients are randomly divided into two groups: one of the groups is given treatment, and the other a placebo. Is this really the only reliable way to evaluate treatment effectiveness, or […]Continue Reading ...
A research team led by scientists and doctors in Leicester and the Netherlands has shown that a urine test to measure whether patients are taking their medications will save the NHS money. The research, published in the journal Hypertension, was conducted in collaboration between the University of Leicester, Leicester’s Hospitals and University of Groningen, Netherlands. […]Continue Reading ...
Researchers at Henry Ford Hospital in Detroit have shown that it may be possible to use ultrasound scans of a muscle in the shoulder to predict diabetes. Sebastian Kaulitzki | Shutterstock The study, which will be presented at the annual meeting of the Radiological Society of North America, suggests that the “deltoid” muscle appearing unusually […]Continue Reading ...
(HealthDay)—Rare but serious genital infections, as well as one death, have been reported in some patients taking a certain class of type 2 diabetes medicine, the U.S. Food and Drug Administration says. As a result, the FDA has ordered a new warning about this risk to be added to the prescribing information and patient medication […]Continue Reading ...
In one of the largest studies to measure the burden of antibiotic resistance in a low- or middle-income country, researchers at the Center for Disease Dynamics, Economics & Policy report that in-hospital mortality is significantly higher among patients infected with multi-drug resistant (MDR) or extensively drug resistant (XDR) pathogens including Staphylococcus aureus, Escherichia coli, Klebsiella […]Continue Reading ...
Breakthrough study shows that radiotherapy toxicity might be reduced by ‘personalized scheduling’ A new clinical study led by the University of Leicester and conducted in the HOPE clinical trials facility at Leicester’s Hospitals has revealed the pivotal role that changing the time of day that a patient receives radiotherapy could play in altering radiotherapy toxicity. […]Continue Reading ...
Before patients receive intravenous (IV) antimicrobial infusion therapy outside of the hospital – whether at home, a doctor’s office or a skilled nursing facility – an infectious diseases (ID) specialist should review the order to ensure the most appropriate treatment, suggest updated guidelines released by the Infectious Diseases Society of America (IDSA). Once they begin […]Continue Reading ...
An international study published in the journal Blood by researchers led by Dr. Elie Haddad, a pediatric immunologist and researcher at CHU Sainte-Justine and professor at Université de Montréal, highlights the urgent need to develop better treatment strategies for patients suffering from severe combined immune deficiency (SCID). This deficiency, better known as “bubble baby disease” […]Continue Reading ...
- Skeletal imitation reveals how bones grow atom-by-atom
- Autism behaviors show unique brain network fingerprints in infants
- Location matters for inflammation clearance
- Towards finding a druggable cancer target
- Ultragenyx Announces Intent to Submit New Drug Application to U.S. FDA for UX007 for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Mid-2019
- Cooling ‘brains on fire’ to treat Parkinson’s
- Less pollution could increase the average lifespan of Copenhageners by an entire year in 2040
- Abramson Cancer Center becomes the 28th member institution of National Comprehensive Cancer Network
- The plug and play time-resolved spectrometer from PicoQuant
- Breakthrough technology offers new hope to people with glaucoma, retinitis and macular degeneration
- New report highlights key focus areas to help cancer screening realize its full potential
- International experts to discuss strategies to maintain spatial orientation in old age
- Scientists discover new inhibitor that decreases lung inflammation
- Participation project calls for relaxing research ban on germline interventions
- Karyopharm’s Selinexor Receives Fast Track Designation from FDA for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
- Arthritis by the Numbers: Book of Trusted Facts & Figures
- Drug homing method helps rethink Parkinson’s
- AHF commends the passage of global AIDS funding in the House, calls for swift approval
- The search for new psychiatric disorder treatments
- New research offers hope for simpler way to diagnose and treat cancer